白细胞介素10检测对乳腺癌患者预后的评估价值  

The valuation value of interleukin-10 for the prognosis of breast cancer patients

作　　者：窦艳[1] 邱鹏[1] 王丽[1] 刘晓丽[1] 庞文帅 Dou Yan;Qiu Peng;Wang Li;Liu Xiaoli;Pang Wenshuai(The People's Hospital of Xingtai City,Hebei Xingtai 054000)

机构地区：[1]邢台市人民医院,河北邢台054000

出　　处：《中国社区医师》2020年第10期122-122,124,共2页Chinese Community Doctors

基　　金：邢台市科技计划项目(项目编号:2018zc147).

摘　　要：目的:探究白细胞介素10(IL-10)检测对乳腺癌患者预后的评估价值。方法:2018年8月-2019年5月收治乳腺癌患者86例,根据化疗疗效分为有效组50例和无效组36例。比较两组患者化疗前后血清IL-10水平。结果:有效组化疗后血清IL-10水平低于无效组,差异有统计学意义(P<0.05)。结论:血清IL-10检测对乳腺癌患者预后的评估具有一定价值,降低血清IL-10水平可能改善预后效果。Objective:To explore the valuation value of interleukin-10 for the prognosis of breast cancer patients.Methods:From August 2018 to May 2019,86 breast cancer patients were selected.According to the chemotherapy effect,they were divided into the effective group(50 cases)and the ineffective group(36 cases).We compared the serum IL-10 levels of the two groups before and after treatment.Results:In the effective group,the level of serum IL-10 after chemotherapy was lower than that in the ineffective group,the difference was statistically significant(P<0.05).Conclusion:The detection of serum IL-10 has a certain value in the evaluation of prognosis of breast cancer patients,lowering the level of serum IL-10 may improve the prognosis.

关 键 词：乳腺癌 白细胞介素10 新辅助化疗 预后 

分 类 号：R737.9[医药卫生—肿瘤]